RE:Sunday morning reading (no mention of Microbix) ... Interesting!
I'm not sure how many of Microbix products deal with all the diseases* that are now on the increase ..,
... but bad news for humanity could be good news for MBX
Re: Covid in particular, Just a reminder that MBX saw an spike in Revenue from VTM during COVID, something that is unlikely to repeat in the same way even with a COVID resurgence. Home test kits, no more free lab tests, and declining morbidity rates mean VTM demand is very unlikely to return to previous levels. However, its use to diagnose other conditions may increase, and of course there is base demand that Microbix could take a bigger share of the market on, particularly in Canada and maybe the US. Still awaiting some news on this.
* Comeback Diseases
Influenza cases in the US have jumped about 40% in the two post-COVID flu seasons, compared with the pre-pandemic years, according to clinical lab results. Whooping cough, or pertussis, cases have climbed by 45 times in China in the first four months compared with last year. And in some parts of Australia, where flu season is just getting underway, cases of respiratory syncytial virus, or RSV, have nearly doubled from a year ago.
Argentina is battling its worst-ever dengue outbreak. Japan is seeing a mysterious surge of Streptococcal A, also known as strep throat. Measles is making a comeback in more than 20 American states, the UK and parts of Europe. Globally, 7.5 million people were newly diagnosed with tuberculosis in 2022 – the worst year on record since the World Health Organisation started global TB monitoring in the mid-1990s.
MM